Sequenom (SQNM) : The consensus on Sequenom (SQNM) based on 4 analyst recommendation on the company stock is 3, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Sequenom (SQNM) : Average target price received by Sequenom (SQNM) is $1.35 with an expected standard deviation of $0.91. The most aggressive target on the stock is $2, whereas the most downbeat target is $1. 3 financial analysts are currently covering the stock.
Shares of Sequenom Inc. rose by 1.7% in the last five trading days and 184.52% for the last 4 weeks. Sequenom Inc. is up 127.62% in the last 3-month period. Year-to-Date the stock performance stands at 45.73%. Sequenom (NASDAQ:SQNM): stock turned positive on Tuesday. Though the stock opened at $2.38, the bulls momentum made the stock top out at $2.39 level for the day. The stock recorded a low of $2.38 and closed the trading day at $2.39, in the green by 1.27%. The total traded volume for the day was 2,653,738. The stock had closed at $2.36 in the previous days trading.
Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.